238 related articles for article (PubMed ID: 24798679)
21. Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain.
Petrosino S; Ahmad A; Marcolongo G; Esposito E; Allarà M; Verde R; Cuzzocrea S; Di Marzo V
Pharmacol Res; 2015 Jan; 91():9-14. PubMed ID: 25447594
[TBL] [Abstract][Full Text] [Related]
22. Second-Generation Non-Covalent NAAA Inhibitors are Protective in a Model of Multiple Sclerosis.
Migliore M; Pontis S; Fuentes de Arriba AL; Realini N; Torrente E; Armirotti A; Romeo E; Di Martino S; Russo D; Pizzirani D; Summa M; Lanfranco M; Ottonello G; Busquet P; Jung KM; Garcia-Guzman M; Heim R; Scarpelli R; Piomelli D
Angew Chem Int Ed Engl; 2016 Sep; 55(37):11193-11197. PubMed ID: 27404798
[TBL] [Abstract][Full Text] [Related]
23. N-acylethanolamine hydrolyzing acid amidase inhibition: tools and potential therapeutic opportunities.
Bottemanne P; Muccioli GG; Alhouayek M
Drug Discov Today; 2018 Aug; 23(8):1520-1529. PubMed ID: 29567427
[TBL] [Abstract][Full Text] [Related]
24. N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis.
Alhouayek M; Bottemanne P; Subramanian KV; Lambert DM; Makriyannis A; Cani PD; Muccioli GG
FASEB J; 2015 Feb; 29(2):650-61. PubMed ID: 25384424
[TBL] [Abstract][Full Text] [Related]
25. Anti-Inflammatory Effects of Fucoxanthinol in LPS-Induced RAW264.7 Cells through the NAAA-PEA Pathway.
Jin W; Yang L; Yi Z; Fang H; Chen W; Hong Z; Zhang Y; Zhang G; Li L
Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32326173
[TBL] [Abstract][Full Text] [Related]
26. N-Acylethanolamine acid amidase (NAAA) inhibitor F215 as a novel therapeutic agent for osteoarthritis.
Zhou P; Xiang L; Yang Y; Wu Y; Hu T; Liu X; Lin F; Xiu Y; Wu K; Lu C; Ren J; Qiu Y; Li Y
Pharmacol Res; 2019 Jul; 145():104264. PubMed ID: 31063807
[TBL] [Abstract][Full Text] [Related]
27. Synergistic antinociceptive effects of concomitant NAAA and peripheral FAAH inhibition.
Mabou Tagne A; Fotio Y; Uppal PS; Piomelli D
Exp Neurol; 2022 Nov; 357():114194. PubMed ID: 35932800
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanism of activation of the immunoregulatory amidase NAAA.
Gorelik A; Gebai A; Illes K; Piomelli D; Nagar B
Proc Natl Acad Sci U S A; 2018 Oct; 115(43):E10032-E10040. PubMed ID: 30301806
[TBL] [Abstract][Full Text] [Related]
29. N-Acylethanolamine acid amidase (NAAA) exacerbates psoriasis inflammation by enhancing dendritic cell (DCs) maturation.
Li Y; Li Y; Xu S; Chen Y; Zhou P; Hu T; Li H; Liu Y; Xu Y; Ren J; Qiu Y; Lu C
Pharmacol Res; 2022 Nov; 185():106491. PubMed ID: 36244543
[TBL] [Abstract][Full Text] [Related]
30. Harnessing the anti-inflammatory potential of palmitoylethanolamide.
Alhouayek M; Muccioli GG
Drug Discov Today; 2014 Oct; 19(10):1632-9. PubMed ID: 24952959
[TBL] [Abstract][Full Text] [Related]
31. N-acylethanolamine-hydrolyzing acid amidase and fatty acid amide hydrolase inhibition differentially affect N-acylethanolamine levels and macrophage activation.
Alhouayek M; Bottemanne P; Makriyannis A; Muccioli GG
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 May; 1862(5):474-484. PubMed ID: 28065729
[TBL] [Abstract][Full Text] [Related]
32. Antinociceptive Profile of ARN19702, (2-Ethylsulfonylphenyl)-[(2S)-4-(6-fluoro-1,3-benzothiazol-2-yl)-2-methylpiperazin-1-yl]methanone, a Novel Orally Active
Fotio Y; Sasso O; Ciccocioppo R; Piomelli D
J Pharmacol Exp Ther; 2021 Aug; 378(2):70-76. PubMed ID: 33986036
[No Abstract] [Full Text] [Related]
33. Genetic Blockade of NAAA Cell-specifically Regulates Fatty Acid Ethanolamides (FAEs) Metabolism and Inflammatory Responses.
Xie X; Li Y; Xu S; Zhou P; Yang L; Xu Y; Qiu Y; Yang Y; Li Y
Front Pharmacol; 2021; 12():817603. PubMed ID: 35069223
[TBL] [Abstract][Full Text] [Related]
34. Synergic Therapeutic Potential of PEA-Um Treatment and NAAA Enzyme Silencing In the Management of Neuroinflammation.
Casili G; Lanza M; Campolo M; Siracusa R; Paterniti I; Ardizzone A; Scuderi SA; Cuzzocrea S; Esposito E
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050589
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors.
Solorzano C; Antonietti F; Duranti A; Tontini A; Rivara S; Lodola A; Vacondio F; Tarzia G; Piomelli D; Mor M
J Med Chem; 2010 Aug; 53(15):5770-81. PubMed ID: 20604568
[TBL] [Abstract][Full Text] [Related]
36. NAAA inhibitor F96 attenuates BBB disruption and secondary injury after traumatic brain injury (TBI).
Li Y; Zhou P; Hu T; Ren J; Xu Y; Qiu Y; Lu C; Li Y
Eur J Pharmacol; 2021 Dec; 912():174561. PubMed ID: 34655598
[TBL] [Abstract][Full Text] [Related]
37. Insights in the mechanism of action and inhibition of N-acylethanolamine acid amidase by means of computational methods.
Lodola A; Rivara S; Mor M
Adv Protein Chem Struct Biol; 2014; 96():219-34. PubMed ID: 25443959
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of N-acylethanolamine acid amidase reduces nicotine-induced dopamine activation and reward.
Sagheddu C; Scherma M; Congiu M; Fadda P; Carta G; Banni S; Wood JT; Makriyannis A; Malamas MS; Pistis M
Neuropharmacology; 2019 Jan; 144():327-336. PubMed ID: 30439418
[TBL] [Abstract][Full Text] [Related]
39. Assay of NAAA Activity.
Tsuboi K; Ueda N
Methods Mol Biol; 2023; 2576():261-274. PubMed ID: 36152194
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.
Tuo W; Leleu-Chavain N; Spencer J; Sansook S; Millet R; Chavatte P
J Med Chem; 2017 Jan; 60(1):4-46. PubMed ID: 27766867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
